Understanding and targeting the tumour matrisome
- 21 September 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- p. 1-21
Abstract
The extracellular matrix (ECM) is a dynamic meshwork of proteins and glycans that provides architectural support to cells. This meshwork also conveys mechanical and biochemical signals that orchestrate many cellular processes, including proliferation, survival and migration. ECM accumulation is a hallmark of cancers and correlates with tumour aggressiveness and survival across cancer types. Because of its abundance and accessibility, the ECM constitutes an appealing reservoir of potential biomarkers and therapeutic targets. Yet, early attempts to target the ECM in patients with cancer have failed to provide clinical benefit. Over the past few years, the development of novel proteomic and imaging methods, together with advances in our knowledge of ECM biology provided by fundamental research, have transformed our understanding of the roles of the ECM in tumour progression. In this Review, we describe novel technologies developed to define the composition, physical and mechanical properties, and signalling functions of the ECM and provide an overview of ECM-dependent mechanisms regulating tumour progression. We then illustrate how the ECM is being leveraged to devise prognostic or diagnostic clinical tests. Lastly, we discuss strategies to target the ECM for clinical benefit by using the ECM for the targeted delivery of therapeutic payloads, normalizing the tumour ECM through matritherapies or modulating ECM signalling pathways.Keywords
This publication has 326 references indexed in Scilit:
- Tripokin: A multi‐specific immunocytokine for cancer immunotherapyInternational Journal of Cancer, 2024
- Molecular analysis of the extracellular microenvironment: from form to functionFEBS Letters, 2024
- MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsGenes, Chromosomes and Cancer, 2021
- Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinomaMolecular Oncology, 2019
- Genetic Disorders of the Extracellular MatrixThe Anatomical Record, 2019
- Circulating and disseminated tumor cells: harbingers or initiators of metastasis?Molecular Oncology, 2017
- Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse modelsIUBMB Life, 2011
- A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanomaCancer, 2010
- Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectinInternational Journal of Cancer, 2002
- Risk for breast cancer development determined by mammographic parenchymal patternCancer, 1976